insights_auto
Zakaj je tečaj EBS zrasel 3,67%?
Podrobneje raziščichevron_right
EBS:NYSE
Emergent BioSolutions
7,06 $
arrow_upward
+3,67%(+0,25) 1D
7,01 $
arrow_downward
−0,71% (−0,050)bedtimePo zaprtju
Zaprto: 9. okt., 16:00:07 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za EBS …
Odpri
6,73 $
Visoka
7,06 $
Nizka
6,60 $
Tržna kapitalizacija
361,99 mio.
Povprečni promet
1,18 mio.
Promet
850,96 tis.
52-tedenski najvišji tečaj
14,06 $
52-tedenski najnižji tečaj
4,36 $
Čisti dobiček na delnico
−3,51 $
Beta
2,28
Št. izdanih delnic
51,27 mio.
Št. zaposlenih
900
Odpri
6,73 $
Visoka
7,06 $
Nizka
6,60 $
Tržna kapitalizacija
361,99 mio.
Povprečni promet
1,18 mio.
Promet
850,96 tis.
52-tedenski najvišji tečaj
14,06 $
52-tedenski najnižji tečaj
4,36 $
Čisti dobiček na delnico
−3,51 $
Beta
2,28
Št. izdanih delnic
51,27 mio.
Št. zaposlenih
900
Novice
Iz spletnih virov in novičarskih partnerjev
Moneycontrol.com
·
pred 48 minutami
'AI is all that matters': How 42 artificial intelligence stocks drive 67% of S&P 500 gains since 2024
Finimize
·
pred 46 minutami
PM Capital Blamed A Narrow US Rally For Its September Dip
Barchart.com
·
pred 6 urami
The S&P 500 Is Near Record Highs. So Why Does Your Portfolio Feel Like a Bear Market?
Yahoo Finance
·
pred 5 urami
XRP’s Nasdaq Moment Nears: 5 Things to Know About Evernorth
Profil
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Vizitka: Emergent BioSolutions
Generalni direktorRobert G. Kramer Sr. | Joseph C. Papa
Št. zaposlenih900
Ustanovljeno5. sep. 1998
SedežRockville, Maryland, Združene države Amerike
Sektor-
Spletno mestoemergentbiosolutions.com